Phathom Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. (PHAT) filed this Current Report on Form 8-K on January 7, 2026, to disclose a significant capital raising event. The Company is a Delaware corporation with principal executive offices in Florham Park, New Jersey.
Key Financial Metrics and Transaction Details
This filing details a public offering of common stock and pre-funded warrants. Key transaction metrics include:
- Common Stock Issuance: 6,875,000 shares at a public offering price of $16.00 per share.
- Pre-Funded Warrants: 1,250,078 warrants at $15.999 per warrant (exercise price of $0.001).
- Underwriter Purchase Price: $15.04 per share and $15.039 per warrant.
- Expected Net Proceeds: Approximately $130 million, or approximately $150 million if the underwriters' option is fully exercised.
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to 1,218,761 additional shares.
- Expected Closing Date: January 9, 2026.
The filing does not provide historical revenue, profit, cash flow, margin, or debt figures as this is a transaction-specific report rather than a periodic financial statement.
Material Changes and Outlook
The primary material change is the execution of an underwriting agreement with Guggenheim Securities, LLC and Cantor Fitzgerald & Co. The Company expects to receive significant liquidity from this offering to fund its operations. Management commentary is limited to the announcement of the offering and standard forward-looking statements regarding the completion of the transaction and satisfaction of closing conditions.
Risks and Contingencies
- Closing Conditions: The offering is subject to customary closing conditions; failure to satisfy these could delay or cancel the transaction.
- Beneficial Ownership Limitations: Pre-Funded Warrants are subject to a 19.99% beneficial ownership limitation, which may restrict the ability of certain holders to exercise warrants immediately.
- Forward-Looking Statements: Actual proceeds and closing dates may differ from expectations due to market conditions and other uncertainties.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received upon completion of the offering.
- Confirm whether the underwriters exercised the 30-day option to purchase additional shares.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) and Pre-Funded Warrant (Exhibit 4.1) for specific covenants and limitations.
- Monitor subsequent filings for the impact of this capital raise on the Company's cash runway and dilution metrics.